New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
Gommermann, N., Buehlmayer, P., von Matt, A., Breitenstein, W., Masuya, K., Pirard, B., Furet, P., Cowan-Jacob, S.W., Weckbecker, G.(2010) Bioorg Med Chem Lett 20: 3628-3631
- PubMed: 20483608 
- DOI: https://doi.org/10.1016/j.bmcl.2010.04.112
- Primary Citation of Related Structures:  
3MPM - PubMed Abstract: 
A novel series of pyrazolo[1,5a]pyrimidines was optimized to target lymphocyte-specific kinase (Lck). An efficient synthetic route was developed and SAR studies toward activity and selectivity are described, leading to Lck inhibitors with enzymatic, cellular and in vivo potency.
Organizational Affiliation: 
Novartis Institute of Biomedical Research, Forum 1, Novartis Campus, Basel, Switzerland. nina.gommermann@novartis.com